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The article “Optimizing management of chronic obstructive pulmonary disease in the 
upcoming decade” by Russell et al1 (January edition of the International Journal of 
Chronic Obstructive Pulmonary Disease) provides an overview of the pathophysiol-
ogy of chronic obstructive pulmonary disease (COPD) and discusses emerging treat-
ment options for managing this disease. I wish to draw your attention to the general 
information and clinical trial data presented on roflumilast. Several inaccuracies have 
been noticed in this section as well as in Table 2 of the article.
The most important of these is the authors’ statement that roflumilast’s therapeu-
tic effects include bronchodilation. Although statistically significant improvements 
in lung function were observed in clinical trials of roflumilast, these improvements 
were not determined to be clinically significant. The US prescribing information for 
roflumilast (DALIRESPTM [Forest Pharmaceuticals, Inc, St Louis, MO]) specifies in 
its indication that DALIRESP is not a bronchodilator and is not indicated for the relief 
of acute bronchospasm.2 The Food and Drug Administration-approved indication for 
DALIRESP is to reduce the risk of COPD exacerbations in patients with severe COPD 
associated with chronic bronchitis and a history of exacerbations.
In addition, Table 1 lists “Current pharmacologic options for the management of 
COPD,” citing the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines, but the class of phosphodiesterase-4 (PDE-4) inhibitors is not listed. 
Considering that this article was published in 2011 and that PDE-4 inhibitors were 
included in the 2010 revision to the GOLD guidelines,3 PDE-4 inhibitors should be 
included in Table 1.
For your reference, I have included a table of additional minor inaccuracies at the 
end of this letter.
It is understood that authors and editors make every effort to provide scientifically 
rigorous and concise reporting, and that errors or inaccuracies in such reporting can 
occur. It is important to identify and correct these so that medical professionals can 
make informed decisions when prescribing medications. I respectfully ask you to 
consider publishing a correction to the information about roflumilast, especially to 
clarify the critical point that it is not indicated for use as a bronchodilator.
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Corrections and comments on reporting of roflumilast clinical data in Russell et al1
Location As stated Corrections/comments
Page 52, column 2 Clinical studies with roflumilast monotherapy  
demonstrated improved lung function,  
reduced moderate-to-severe exacerbations,  
reduced requirement for anti-inflammatory/ 
anti-infective medications,  
and improved QoL measures4,5
Calverley et al4 showed a significant reduction in the  
rate of exacerbations requiring treatment with systemic 
corticosteroids, antibiotics, or both (P = 0.0003);  
however, neither study directly measured whether  
the requirement for anti-inflammatory/anti-infective 
medications was reduced or otherwise affected  
by roflumilast treatment
Page 52, column 2 Similarly, improvements in lung function and  
exacerbation outcomes were reported when  
roflumilast was added to tiotropium, or  
to salmeterol plus fluticasone6
Fabbri et al6 described two studies: one in which  
roflumilast was added to tiotropium alone  
and one in which roflumilast was added to  
salmeterol alone. No study added roflumilast  
to salmeterol plus fluticasone
Page 52, column 2 Notable side effects with roflumilast include  
headache, weight loss (2.5 kg in all studies at  
six months and one year), diarrhea, nausea,  
and stomach ache (ie, gastrointestinal  
side effects that resulted in a significant  
early study withdrawal rate)4–6
The source of the 2.5 kg value is unclear.  
Calverley et al4 reported between-treatment  
weight loss as -2.17 kg; Rabe et al5 reported  
between-treatment weight loss as -2.2 kg;  
Fabbri et al6 reported between-treatment  
weight loss as -2.1 kg
Page 52, column 2 Notable side effects with roflumilast include  
headache, weight loss (2.5 kg in all studies  
at six months and one year), diarrhea, nausea,  
and stomach ache (ie, gastrointestinal  
side effects that resulted in a significant  
early study withdrawal rate)4–6
Stomach ache is not reported as a side effect  
in any of the clinical papers cited
Page 52, column 2 Notable side effects with roflumilast include  
headache, weight loss (2.5 kg in all studies  
at six months and one year), diarrhea, nausea,  
and stomach ache (ie, gastrointestinal  
side effects that resulted in a significant  
early study withdrawal rate)4–6
Only one study reported that gastrointestinal  
side effects resulted in early study withdrawal4
Table 2, column 1, line 35 Study: M2–124 and M1–125 Study number should be listed as M2–125,  
not M1–125
Table 2, column 1, lines 38–40 Assessed roflumilast 500 μg once daily  
versus placebo in symptomatic moderate- 
to-severe COPD
Patient population in Calverley et al4 is  
severe-to-very severe, not moderate-to-severe
Table 2, column 1, line 55 Total n = 933 The total n should be 7434
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